Carmen Rodríguez

Carmen Rodríguez

Auto-generated profile, based on publicly available information

Carmen Rodríguez

Centro Sanitario Sandoval, Madrid, Spain

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2009 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
Eva PovedaEva Poveda
Eva Poveda
ESEduardo SecléN
Eduardo SecléN
MGMaríA del Mar GonzáLez
MaríA del Mar GonzáLez
FGFederico GarcíA
Federico GarcíA
NCNatalia Chueca
Natalia Chueca
VSVincent Soriano
Vincent Soriano
Genotypic tools may allow easier and less expensive estimation of HIV tropism before prescription of CCR5 antagonists compared with the Trofile® assay (Monogram Biosciences, South San Francisco, CA, USA). Paired genotypic and Trofile® results were compared in plasma samples derived from the maraviroc expanded access programme (EAP) in Europe. A new genotypic approach was built to improve the sensitivity to detect X4 variants based on an optimization of the webPSSM algorithm. Then, the new tool was validated in specimens from patients included in the ALLEGRO trial, a multicentre study conducted in Spain to assess the prevalence of R5 variants in treatment-experienced HIV patients. A total of 266 specimens from the maraviroc EAP were tested. Overall geno/pheno concordance was above 72%. A high specificity was generally seen for the detection of X4 variants using genotypic tools (ranging from 58% to 95%), while sensitivity was low (ranging from 31% to 76%). The PSSM score was then optimized to enhance the sensitivity to detect X4 variants changing the original threshold for R5 categorization. The new PSSM algorithms, PSSMX4R5-8 and PSSMSINSI-6.4, considered as X4 all V3 scoring values above −8 or −6.4, respectively, increasing the sensitivity to detect X4 variants up to 80%. The new algorithms were then validated in 148 specimens derived from patients included in the ALLEGRO trial. The sensitivity/specificity to detect X4 variants was 93%/69% for PSSMX4R5-8 and 93%/70% for PSSMSINSI-6.4. PSSMX4R5-8 and PSSMSINSI-6.4 may confidently assist therapeutic decisions for using CCR5 antagonists in HIV patients, providing an easier and rapid estimation of tropism in clinical samples.

23 March 2012 in Virology Journal
Verified
Journal Article
Open access
PDF file
ATAna Treviño
Ana Treviño
AAAntonio Aguilera
Antonio Aguilera
ECEstrella Caballero
Estrella Caballero
RBRafael Benito
Rafael Benito
PPPatricia Parra
Patricia Parra
VSVicente Soriano
Vicente Soriano
Although most HTLV infections in Spain have been found in native intravenous drug users carrying HTLV-2, the large immigration flows from Latin America and Sub-Saharan Africa in recent years may have changed the prevalence and distribution of HTLV-1 and HTLV-2 infections, and hypothetically open the opportunity for introducing HTLV-3 or HTLV-4 in Spain. To assess the current seroprevalence of HTLV infection in Spain a national multicenter, cross-sectional, study was conducted in June 2009. A total of 6,460 consecutive outpatients attending 16 hospitals were examined. Overall, 12% were immigrants, and their main origin was Latin America (4.9%), Africa (3.6%) and other European countries (2.8%). Nine individuals were seroreactive for HTLV antibodies (overall prevalence, 0.14%). Evidence of HTLV-1 infection was confirmed by Western blot in 4 subjects (prevalence 0.06%) while HTLV-2 infection was found in 5 (prevalence 0.08%). Infection with HTLV types 1, 2, 3 and 4 was discarded by Western blot and specific PCR assays in another two specimens initially reactive in the enzyme immunoassay. All but one HTLV-1 cases were Latin-Americans while all persons with HTLV-2 infection were native Spaniards. The overall prevalence of HTLV infections in Spain remains low, with no evidence of HTLV-3 or HTLV-4 infections so far.

1 June 2009 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
ATAna Treviño
Ana Treviño
AAAntonio Aguilera
Antonio Aguilera
ECEstrella Caballero
Estrella Caballero
CTCarlos Toro
Carlos Toro
JEJosé M. Eiros
José M. Eiros
VSVincent Soriano
Vincent Soriano
HTLV-1/2 antenatal screening is not mandatory in European countries. The rapid increase in immigrants coming from areas endemic for HTLV-1 infection has compelled a review of this policy in Spain. From February 2006 to December 2007, a cross-sectional study was carried out in all pregnant women attended at 10 different Spanish hospitals. An enzyme immunoassay (EIA) was used to test serum HTLV-1/2 antibodies; reactive samples were further confirmed by Western blot and/or polymerase chain reaction. A total of 20,518 pregnant women were examined, of whom 18,266 (89%) were native Spaniards. Overall, 946 (4.6%) of the immigrants came from HTLV-1 endemic areas (mainly Central and South America and sub-Saharan Africa). Four samples were EIA seroreactive for HTLV-1/2, two of them in women infected with HTLV-1 coming from endemic areas. The other two women were infected with HTLV-2; one was an immigrant from Bolivia and another was a native Spaniard who admitted prior injection drug use and was HIV-1 positive. The overall HTLV-1/2 seroprevalence was 0.19 per 1000 (95% CI: 0.05–0.49/1000). For HTLV-1, the seroprevalence was 2.11 per 1000 (95% CI: 0.26–7.62/1000) in pregnant women from endemic areas. The seroprevalence of HTLV-1/2 infection is below 0.02% among pregnant women in Spain, and therefore universal screening for HTLV-1/2 infection in antenatal clinics is not warranted. However, HTLV-1/2 screening could be considered in pregnant women coming from endemic areas, in whom the rate of infection is nearly 1000-fold higher than in native Spaniards and are the only group infected with the more pathogenic HTLV-1.

13 October 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BRBenito Regueiro
Benito Regueiro
EVEduardo Varela-Ledo
Eduardo Varela-Ledo
LMLucia Martinez-Lamas
Lucia Martinez-Lamas
JRJavier Rodriguez-Calviño
Javier Rodriguez-Calviño
AAAntonio Aguilera
Antonio Aguilera
JAJulian Alvarez-Escudero
Julian Alvarez-Escudero
Sepsis is one of the leading causes of morbidity and mortality in hospitalized patients worldwide. Molecular technologies for rapid detection of microorganisms in patients with sepsis have only recently become available. LightCycler SeptiFast test Mgrade (Roche Diagnostics GmbH) is a multiplex PCR analysis able to detect DNA of the 25 most frequent pathogens in bloodstream infections. The time and labor saved while avoiding excessive laboratory manipulation is the rationale for selecting the automated MagNA Pure compact nucleic acid isolation kit-I (Roche Applied Science, GmbH) as an alternative to conventional SeptiFast extraction. For the purposes of this study, we evaluate extraction in order to demonstrate the feasibility of automation. Finally, a prospective observational study was done using 106 clinical samples obtained from 76 patients in our ICU. Both extraction methods were used in parallel to test the samples. When molecular detection test results using both manual and automated extraction were compared with the data from blood cultures obtained at the same time, the results show that SeptiFast with the alternative MagNA Pure compact extraction not only shortens the complete workflow to 3.57 hrs., but also increases sensitivity of the molecular assay for detecting infection as defined by positive blood culture confirmation.

1 September 2018 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
AAAntonio Aguilera
Antonio Aguilera
RTRocío Trastoy-Pena
Rocío Trastoy-Pena
JRJavier Rodríguez-Calviño
Javier Rodríguez-Calviño
TGTamara Manso Gómez
Tamara Manso Gómez
CMCarmen de Mendoza
Carmen de Mendoza
VSVicente Soriano
Vicente Soriano
Background: Hepatitis delta virus (HDV) is a defective agent that only replicates in the presence of the hepatitis B virus. Accordingly, HDV acquisition may occur as superinfection of HBsAg+ carriers or following acute dual HDV and hepatitis B virus exposure. Herein, we examined the global and incident rates of HDV infections in Spain. Patients and methods: The presence of anti-HDV antibody and new HDV superinfections was examined in all HBsAg+ patients who attended one large tertiary outclinic in Spain since year 2000. Anti-HDV antibodies were tested repeatedly every 5 years in those previously negative. Results: During a median follow-up of 12 years, 478 individuals were diagnosed as HBsAg+. Overall, 64.4% were male, median age was 55 years, 88.1% were native Spaniards, 6.5% were coinfected with HIV, and 7.3% were reactive for hepatitis C virus (HCV) antibodies. A total of 19 (4%) patients had anti-HDV antibody at first diagnosis. There were no further HDV seroconversions. Most anti-HDV+ patients were male (n=12), former injection drug users (n=13), and native Spaniards (n=16). Coinfection with HIV was found in six, and 12 had HCV antibodies. Interestingly, three of seven women with delta hepatitis were foreigners (Asian or African), denied injection drug use, were younger than 40 years old, and negative for both HCV and HIV. Conclusion: The prevalence of chronic hepatitis delta is currently very low (<5%) among chronic HBsAg+ carriers in Spain, with lower rates in recent years. Moreover, new incident HDV infections were not seen in 478 chronic hepatitis B carriers since year 2000, following drastic declines in injection drug use.

31 July 2017 in AIDS
Verified
Journal Article
Closed access
CMCarmen de Mendoza
Carmen de Mendoza
ECEstrella Caballero
Estrella Caballero
AAAntonio Aguilera
Antonio Aguilera
SRSilvia Requena
Silvia Requena
RLRaúl Ortiz de Lejarazu
Raúl Ortiz de Lejarazu
VSVicente Soriano
Vicente Soriano
Human T-lymphotropic virus type 1 (HTLV-1) infection is a neglected disease despite roughly 15 million people are chronically infected worldwide. Lifelong less than 10% of carriers develop life-threatening diseases, mostly a subacute myelopathy known as tropical spastic paraparesis (TSP) and a lymphoproliferative disorder named adult T-cell leukemia (ATL). HTLV-1 is efficiently transmitted perinatally (breastfeeding), sexually (more from men to women) and parenterally (transfusions, injection drug user (IDU), and transplants). To date there is neither prophylactic vaccine nor effective antiviral therapy. A total of 327 cases of HTLV-1 infection had been reported at the HTLV-1 Spanish registry until December 2016, of whom 34 had been diagnosed with TSP and 25 with ATL. Overall 62% were Latin American immigrants and 13% were persons of African origin. The incidence of HTLV-1 in Spain has remained stable for nearly a decade with 20–25 new cases yearly. Of the 21 newly diagnosed HTLV-1 cases during year 2016, one was a native Spaniard pregnant woman, and four presented with symptomatic disease, including three with ATL and one with TSP. Underdiagnosis of HTLV-1 in Spain must be high (iceberg model), which may account for the disproportionate high rate of symptomatic cases (almost 20%) and the late recognition of preventable HTLV-1 transmissions in special populations, such as newborns and transplant recipients. Our current estimate is of 10 000 persons living with HTLV-1 infection in Spain. Given the large flux of immigrants and visitors from HTLV-1 endemic regions to Spain, the expansion of HTLV-1 screening policies is warranted. At this time, it seems worth recommending HTLV testing to all donor/recipient organ transplants and pregnant women regardless place of birth. Although current leukoreduction procedures largely prevent HTLV-1 transmission by blood transfusions, HTLV testing of all first-time donors should be cost-effective contributing to unveil asymptomatic unaware HTLV-1 carriers.